Friday, 16 October 2026European Markets

AUSTEVOLL SEAFOOD Stock Over 9% Up So Far Today

Loading stream...

(VIANEWS) - Shares of AUSTEVOLL SEAFOOD (Oslo Børs Benchmark Index_GI: AUSS.OL) jumped 9.91% to kr97.05 at 14:23 EST on Thursday, after two successive sessions in a row of losses. Oslo Børs Benchmark Index_GI is jumping 0.82% to kr1,231.28, following the last session's downward trend. This seems, up until now, a somewhat up trend exchanging session today.

About AUSTEVOLL SEAFOOD

Austevoll Seafood ASA, a seafood company, engages in the salmon and trout, white fish, and pelagic businesses in Norway, the European Union, the United Kingdom, Eastern Europe, Africa, North America, Asia, South America, and internationally. The company is involved in the ownership and operation of fishing vessels, as well as farming, aquaculture, processing, sale, and distribution of salmon and trout. It also produces white fish products, freezing and canning plants, fish meals, and fish oils; omega-3 oil; and canned and frozen fish products. The company was incorporated in 1981 and is headquartered in Storebø, Norway. Austevoll Seafood ASA is a subsidiary of Laco AS.

Earnings Per Share

As for profitability, AUSTEVOLL SEAFOOD has a trailing twelve months EPS of kr13.04.

PE Ratio

AUSTEVOLL SEAFOOD has a trailing twelve months price to earnings ratio of 7.44. Meaning, the purchaser of the share is investing kr7.44 for every norwegian krone of annual earnings.

Volatility

AUSTEVOLL SEAFOOD's last week, last month's, and last quarter's current intraday variation average was a negative 1.12%, a negative 0.59%, and a positive 1.54%.

AUSTEVOLL SEAFOOD's highest amplitude of average volatility was 1.26% (last week), 1.60% (last month), and 1.54% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AUSTEVOLL SEAFOOD's stock is considered to be overbought (>=80).

More news about AUSTEVOLL SEAFOOD (AUSS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com